Literature DB >> 21945393

Wild type and P301L mutant Tau promote neuro-inflammation and α-Synuclein accumulation in lentiviral gene delivery models.

Preeti J Khandelwal1, Sonya B Dumanis, Alexander M Herman, G William Rebeck, Charbel E-H Moussa.   

Abstract

Neurodegeneration involves multiple pathogenic proteins, including Tau, Aβ, TDP-43 and α-Synuclein, but there is little information how these pathogenic proteins interact. We cloned human wild type 4 repeat Tau (Tau(wt)) and mutant Tau(P301L) into a lentivirus and performed stereotaxic injection into the rat motor cortex to examine Tau modification, neuro-inflammation and changes of other proteins associated with neurodegeneration. Tau(P301L) was associated with more phosphorylation of Tau, including Thr 181 and Ser 262 residues and resulted in more aggregation. Both forms of Tau expression increased glycogen synthase kinase-3 (GSK-3) activity, polo-like kinase-2 (PLK2) levels and decreased protein phosphatase activity, but had no effects on casein kinase-1 (CK1). No changes were observed in glial fibrillary acidic protein (GFAP) staining with either Tau(wt) or Tau(P301L), but both caused microglial changes and higher interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels. Tau(wt) and Tau(P301L) increased the levels of endogenous α-Synuclein, but not β-amyloid precursor protein (βAPP) or Tar-DNA binding protein (TDP-43). The levels of phosphorylated Ser-129 α-Synuclein (p-Ser129) were also increased with Tau(wt) and Tau(P301L) expressing animals. These data suggest that Tau(wt) and Tau(P301L) alter kinase activities, but they differentially induce inflammation, Tau modification and α-Synuclein phosphorylation. This change of α-Synuclein in Tau gene transfer models suggests that Tau pathology may lead to α-Synuclein modification in neurodegenerative diseases.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21945393      PMCID: PMC3246111          DOI: 10.1016/j.mcn.2011.09.002

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  45 in total

1.  Association of an extended haplotype in the tau gene with progressive supranuclear palsy.

Authors:  M Baker; I Litvan; H Houlden; J Adamson; D Dickson; J Perez-Tur; J Hardy; T Lynch; E Bigio; M Hutton
Journal:  Hum Mol Genet       Date:  1999-04       Impact factor: 6.150

2.  Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.

Authors:  Olga Pletnikova; Neva West; Michael K Lee; Gay L Rudow; Richard L Skolasky; Ted M Dawson; Laura Marsh; Juan C Troncoso
Journal:  Neurobiol Aging       Date:  2004-12-28       Impact factor: 4.673

3.  Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration.

Authors:  Makoto Higuchi; Takeshi Ishihara; Bin Zhang; Ming Hong; Athena Andreadis; John Trojanowski; Virginia M-Y Lee
Journal:  Neuron       Date:  2002-08-01       Impact factor: 17.173

4.  Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer model.

Authors:  Preeti J Khandelwal; Sonya B Dumanis; Li Rebekah Feng; Kathleen Maguire-Zeiss; Gw Rebeck; Hilal A Lashuel; Charbel Eh Moussa
Journal:  Mol Neurodegener       Date:  2010-11-04       Impact factor: 14.195

5.  Parkin promotes intracellular Abeta1-42 clearance.

Authors:  Mark P Burns; Lihua Zhang; G William Rebeck; Henry W Querfurth; Charbel E-H Moussa
Journal:  Hum Mol Genet       Date:  2009-05-29       Impact factor: 6.150

6.  Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules.

Authors:  B Trinczek; J Biernat; K Baumann; E M Mandelkow; E Mandelkow
Journal:  Mol Biol Cell       Date:  1995-12       Impact factor: 4.138

7.  Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model.

Authors:  Ronald L Klein; Robert D Dayton; Karen M Henderson; Leonard Petrucelli
Journal:  Neurosci Lett       Date:  2006-03-22       Impact factor: 3.046

8.  Distribution of cortical neurofibrillary tangles in progressive supranuclear palsy: a quantitative analysis of six cases.

Authors:  P R Hof; A Delacourte; C Bouras
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

9.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

Authors:  M Goedert; M G Spillantini; R Jakes; D Rutherford; R A Crowther
Journal:  Neuron       Date:  1989-10       Impact factor: 17.173

10.  Overexpression of the human NFM subunit in transgenic mice modifies the level of endogenous NFL and the phosphorylation state of NFH subunits.

Authors:  P H Tu; G Elder; R A Lazzarini; D Nelson; J Q Trojanowski; V M Lee
Journal:  J Cell Biol       Date:  1995-06       Impact factor: 10.539

View more
  27 in total

1.  Selective Neuronal Vulnerability in Alzheimer's Disease: A Network-Based Analysis.

Authors:  Jean-Pierre Roussarie; Vicky Yao; Patricia Rodriguez-Rodriguez; Rose Oughtred; Jennifer Rust; Zakary Plautz; Shirin Kasturia; Christian Albornoz; Wei Wang; Eric F Schmidt; Ruth Dannenfelser; Alicja Tadych; Lars Brichta; Alona Barnea-Cramer; Nathaniel Heintz; Patrick R Hof; Myriam Heiman; Kara Dolinski; Marc Flajolet; Olga G Troyanskaya; Paul Greengard
Journal:  Neuron       Date:  2020-06-29       Impact factor: 17.173

2.  Polymeric alkylpyridinium salts permit intracellular delivery of human Tau in rat hippocampal neurons: requirement of Tau phosphorylation for functional deficits.

Authors:  Dave J Koss; Lianne Robinson; Anna Mietelska-Porowska; Anna Gasiorowska; Kristina Sepčić; Tom Turk; Marcel Jaspars; Grazyna Niewiadomska; Roderick H Scott; Bettina Platt; Gernot Riedel
Journal:  Cell Mol Life Sci       Date:  2015-06-13       Impact factor: 9.261

Review 3.  Targeting Inflammatory Pathways in Alzheimer's Disease: A Focus on Natural Products and Phytomedicines.

Authors:  Matthew J Sharman; Giuseppe Verdile; Shanmugam Kirubakaran; Cristina Parenti; Ahilya Singh; Georgina Watt; Tim Karl; Dennis Chang; Chun Guang Li; Gerald Münch
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

Review 4.  Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.

Authors:  Xuling Li; Simon James; Peng Lei
Journal:  J Mol Neurosci       Date:  2016-09-15       Impact factor: 3.444

5.  Gene Therapy Models of Alzheimer's Disease and Other Dementias.

Authors:  Benjamin Combs; Andrew Kneynsberg; Nicholas M Kanaan
Journal:  Methods Mol Biol       Date:  2016

Review 6.  Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis.

Authors:  Thomas L Platt; Valerie L Reeves; M Paul Murphy
Journal:  Biochim Biophys Acta       Date:  2013-04-22

7.  Fractalkine signaling and Tau hyper-phosphorylation are associated with autophagic alterations in lentiviral Tau and Aβ1-42 gene transfer models.

Authors:  Michaeline L Hebron; Norah K Algarzae; Irina Lonskaya; Charbel Moussa
Journal:  Exp Neurol       Date:  2013-01-16       Impact factor: 5.330

8.  Lentiviral delivery of the human wild-type tau protein mediates a slow and progressive neurodegenerative tau pathology in the rat brain.

Authors:  Raphaëlle Caillierez; Séverine Bégard; Katia Lécolle; Vincent Deramecourt; Nadège Zommer; Simon Dujardin; Anne Loyens; Noëlle Dufour; Gwennaëlle Aurégan; Joris Winderickx; Philippe Hantraye; Nicole Déglon; Luc Buée; Morvane Colin
Journal:  Mol Ther       Date:  2013-04-23       Impact factor: 11.454

9.  Decreased parkin solubility is associated with impairment of autophagy in the nigrostriatum of sporadic Parkinson's disease.

Authors:  I Lonskaya; M L Hebron; N K Algarzae; N Desforges; C E-H Moussa
Journal:  Neuroscience       Date:  2012-12-20       Impact factor: 3.590

10.  The role of telomerase protein TERT in Alzheimer's disease and in tau-related pathology in vitro.

Authors:  Alison Spilsbury; Satomi Miwa; Johannes Attems; Gabriele Saretzki
Journal:  J Neurosci       Date:  2015-01-28       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.